168 related articles for article (PubMed ID: 38463391)
21. Development of a novel redirected T-cell-based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia.
Miyazaki Y; Fujiwara H; Asai H; Ochi F; Ochi T; Azuma T; Ishida T; Okamoto S; Mineno J; Kuzushima K; Shiku H; Yasukawa M
Blood; 2013 Jun; 121(24):4894-901. PubMed ID: 23641014
[TBL] [Abstract][Full Text] [Related]
22. Diepitope multiple antigen peptide of hTERT trigger stronger anti-tumor immune responses in vitro.
Liao ZL; Luo G; Xie X; Tang XD; Bai JY; Guo H; Yang SM
Int Immunopharmacol; 2013 Aug; 16(4):444-50. PubMed ID: 23714071
[TBL] [Abstract][Full Text] [Related]
23. Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia.
Khoury HJ; Collins RH; Blum W; Stiff PS; Elias L; Lebkowski JS; Reddy A; Nishimoto KP; Sen D; Wirth ED; Case CC; DiPersio JF
Cancer; 2017 Aug; 123(16):3061-3072. PubMed ID: 28411378
[TBL] [Abstract][Full Text] [Related]
24. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase.
Parkhurst MR; Riley JP; Igarashi T; Li Y; Robbins PF; Rosenberg SA
Clin Cancer Res; 2004 Jul; 10(14):4688-98. PubMed ID: 15269141
[TBL] [Abstract][Full Text] [Related]
25. Telomerase in cancer immunotherapy.
Liu JP; Chen W; Schwarer AP; Li H
Biochim Biophys Acta; 2010 Jan; 1805(1):35-42. PubMed ID: 19751801
[TBL] [Abstract][Full Text] [Related]
26. A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors.
Teixeira L; Medioni J; Garibal J; Adotevi O; Doucet L; Durey MD; Ghrieb Z; Kiladjian JJ; Brizard M; Laheurte C; Wehbe M; Pliquet E; Escande M; Defrance R; Culine S; Oudard S; Wain-Hobson S; Doppler V; Huet T; Langlade-Demoyen P
Clin Cancer Res; 2020 Feb; 26(3):588-597. PubMed ID: 31558479
[TBL] [Abstract][Full Text] [Related]
27. Safety, tolerability and immunogenicity of V934/V935 hTERT vaccination in cancer patients with selected solid tumors: a phase I study.
Aurisicchio L; Fridman A; Mauro D; Sheloditna R; Chiappori A; Bagchi A; Ciliberto G
J Transl Med; 2020 Jan; 18(1):39. PubMed ID: 32000810
[TBL] [Abstract][Full Text] [Related]
28. Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer.
Kouiavskaia DV; Berard CA; Datena E; Hussain A; Dawson N; Klyushnenkova EN; Alexander RB
J Immunother; 2009; 32(6):655-66. PubMed ID: 19483644
[TBL] [Abstract][Full Text] [Related]
29. Myeloid dendritic cells loaded with dendritic tandem multiple antigenic telomerase reverse transcriptase (hTERT) epitope peptides: a potentially promising tumor vaccine.
Niu BL; Du HM; Shen HP; Lian ZR; Li JZ; Lai X; Wei SD; Zou LQ; Gong JP
Vaccine; 2012 May; 30(23):3395-404. PubMed ID: 22480929
[TBL] [Abstract][Full Text] [Related]
30. The HLA A*0201-restricted hTERT(540-548) peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor.
Purbhoo MA; Li Y; Sutton DH; Brewer JE; Gostick E; Bossi G; Laugel B; Moysey R; Baston E; Liddy N; Cameron B; Bennett AD; Ashfield R; Milicic A; Price DA; Classon BJ; Sewell AK; Jakobsen BK
Mol Cancer Ther; 2007 Jul; 6(7):2081-91. PubMed ID: 17620437
[TBL] [Abstract][Full Text] [Related]
31. A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T
Rebucci-Peixoto M; Vienot A; Adotevi O; Jacquin M; Ghiringhelli F; de la Fouchardière C; You B; Maurina T; Kalbacher E; Bazan F; Meynard G; Clairet AL; Fagnoni-Legat C; Spehner L; Bouard A; Vernerey D; Meurisse A; Kim S; Borg C; Mansi L
Front Oncol; 2022; 12():957580. PubMed ID: 35928870
[TBL] [Abstract][Full Text] [Related]
32. Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells.
Kokhaei P; Palma M; Hansson L; Osterborg A; Mellstedt H; Choudhury A
Exp Hematol; 2007 Feb; 35(2):297-304. PubMed ID: 17258078
[TBL] [Abstract][Full Text] [Related]
33. Interferon-gamma differentially regulates susceptibility of lung cancer cells to telomerase-specific cytotoxic T lymphocytes.
Tajima K; Ito Y; Demachi A; Nishida K; Akatsuka Y; Tsujimura K; Hida T; Morishima Y; Kuwano H; Mitsudomi T; Takahashi T; Kuzushima K
Int J Cancer; 2004 Jun; 110(3):403-12. PubMed ID: 15095306
[TBL] [Abstract][Full Text] [Related]
34. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients.
Sabbatini P; Tsuji T; Ferran L; Ritter E; Sedrak C; Tuballes K; Jungbluth AA; Ritter G; Aghajanian C; Bell-McGuinn K; Hensley ML; Konner J; Tew W; Spriggs DR; Hoffman EW; Venhaus R; Pan L; Salazar AM; Diefenbach CM; Old LJ; Gnjatic S
Clin Cancer Res; 2012 Dec; 18(23):6497-508. PubMed ID: 23032745
[TBL] [Abstract][Full Text] [Related]
35. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer.
Brunsvig PF; Aamdal S; Gjertsen MK; Kvalheim G; Markowski-Grimsrud CJ; Sve I; Dyrhaug M; Trachsel S; Møller M; Eriksen JA; Gaudernack G
Cancer Immunol Immunother; 2006 Dec; 55(12):1553-64. PubMed ID: 16491401
[TBL] [Abstract][Full Text] [Related]
36. Uses of telomerase peptides in anti-tumor immune therapy.
Li H; Katik I; Liu JP
Methods Mol Biol; 2007; 405():61-86. PubMed ID: 18369818
[TBL] [Abstract][Full Text] [Related]
37. Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial.
Schuhmacher J; Heidu S; Balchen T; Richardson JR; Schmeltz C; Sonne J; Schweiker J; Rammensee HG; Thor Straten P; Røder MA; Brasso K; Gouttefangeas C
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33184050
[TBL] [Abstract][Full Text] [Related]
38. Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity.
Yan J; Pankhong P; Shin TH; Obeng-Adjei N; Morrow MP; Walters JN; Khan AS; Sardesai NY; Weiner DB
Cancer Immunol Res; 2013 Sep; 1(3):179-189. PubMed ID: 24777680
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity of a recombinant lentiviral vector carrying human telomerase tumor antigen in HLA-B*0702 transgenic mice.
Rusakiewicz S; Dosset M; Mollier K; Souque P; Charneau P; Wain-Hobson S; Langlade-Demoyen P; Adotévi O
Vaccine; 2010 Aug; 28(38):6374-81. PubMed ID: 20654669
[TBL] [Abstract][Full Text] [Related]
40. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8
Dey S; Sutanto-Ward E; Kopp KL; DuHadaway J; Mondal A; Ghaban D; Lecoq I; Zocca MB; Merlo LMF; Mandik-Nayak L; Andersen MH; Pedersen AW; Muller AJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]